XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Description of Business (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2021
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 14, 2021
Subsidiary, Sale of Stock [Line Items]                    
Net income (loss) attributable to parent   $ (20,276,000) $ (23,471,000) $ (17,501,000) $ (19,433,000) $ (15,601,000) $ 6,401,000 $ (61,248,000) $ (28,633,000)  
Net cash used in operating activities               76,138,000 24,344,000  
Accrued litigation settlement               (15,000,000) $ (15,000,000)  
Cash and cash equivalents $ 146,256,000 65,572,000           65,572,000    
Accumulated deficit 422,882,000 $ 484,130,000           $ 484,130,000    
Pharmakon Term Loans | Secured Debt                    
Subsidiary, Sale of Stock [Line Items]                    
Debt instrument, face amount 125,000,000                  
Tranche A Loan | Secured Debt                    
Subsidiary, Sale of Stock [Line Items]                    
Debt instrument, face amount 75,000,000                 $ 75,000
Proceeds from issuance of secured debt 68,695,000                  
Tranche B Loan | Secured Debt                    
Subsidiary, Sale of Stock [Line Items]                    
Debt instrument, face amount $ 50,000,000                 $ 50,000